Ulcerative Colitis

An association between moderate to severe atopic dermatitis and inflammatory bowel disease suggests a multidisciplinary approach to AD may be necessary, according to a study.

The FDA’s approval of Zymfentra in fall 2023 offers patients the “flexibility” of a subcutaneous therapy option for moderately to severely active ulcerative colitis and Crohn’s disease, Stephen B. Hanauer, MD, told Healio in an interview.

Inflammatory bowel disease phenotype and behavior vary by race and immigration status, with foreign-born patients of all races experiencing less severe disease and later onset than those born in the U.S., researchers reported.

Adam S. Cheifetz, MD, director of the Center for Inflammatory Bowel Disease, medical director of Infusion Services at Beth Israel Deaconess Medical Center, and professor of medicine at Harvard Medical School, spoke with Healio about ulcerative colitis.

Adam S. Cheifetz, MD, director of the Center for Inflammatory Bowel Disease, medical director of Infusion Services at Beth Israel Deaconess Medical Center, and professor of medicine at Harvard Medical School, spoke with Healio about ulcerative colitis.

Adam S. Cheifetz, MD, director of the Center for Inflammatory Bowel Disease, medical director of Infusion Services at Beth Israel Deaconess Medical Center, and professor of medicine at Harvard Medical School, spoke with Healio about ulcerative colitis.

Adam S. Cheifetz, MD, director of the Center for Inflammatory Bowel Disease, medical director of Infusion Services at Beth Israel Deaconess Medical Center, and professor of medicine at Harvard Medical School, spoke with Healio about ulcerative colitis.

Adam S. Cheifetz, MD, director of the Center for Inflammatory Bowel Disease, medical director of Infusion Services at Beth Israel Deaconess Medical Center, and professor of medicine at Harvard Medical School, spoke with Healio about ulcerative colitis.

VANCOUVER, British Columbia — In this Healio video exclusive, Onyinye Ugonabo, MD, reviews the case of young patient who presented with symptoms of ulcerative colitis following discontinuation of growth hormone therapy.

Throughout 2023, gastroenterology societies made several significant clinical practice updates to guide diagnosis, management and treatment of various GI disorders such as celiac disease, inflammatory bowel disease and acute liver failure.